Once-daily tacrolimus in liver transplantation: a 'me-too drug', or a therapeutic advantage

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F17%3A00075926" target="_blank" >RIV/00023001:_____/17:00075926 - isvavai.cz</a>

Výsledek na webu

<a href="https://insights.ovid.com/crossref?an=00075200-201704000-00005#" target="_blank" >https://insights.ovid.com/crossref?an=00075200-201704000-00005#</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MOT.0000000000000387" target="_blank" >10.1097/MOT.0000000000000387</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Once-daily tacrolimus in liver transplantation: a 'me-too drug', or a therapeutic advantage

Popis výsledku v původním jazyce

Purpose of review To provide latest information on differences between standard tacrolimus ( TAC BID) and slow-released formulation of tacrolimus ( Advagraf) in liver transplantation ( LTx), and to discuss the latter&apos;s therapeutic value as a distinct entity. Recent findings Two articles on de-novo studies, several on conversion and one on survival analysis from the European Liver Transplant Registry published recently showed that low-dose Advagraf immediately after transplantation provided same protection to the kidney as standard dose delayed until day 5, and was associated with lower rejection rate; to maintain the same trough level after late conversion to Advagraf, an approximately 1.25-fold higher dose was needed on average; if studied by questionnaire, conversion improved medication adherence; and registry data provided evidence of long-term survival benefit of Advagraf over TAC BID ( 7 and 8% graft and patient survival rates over a 3-year period; P&lt;0.002 and P&lt;0.003, respectively). Summary Pharmacokinetic differences between TAC BID and Advagraf translate into less interpatient and intrapatient variability and improve adherence. If survival benefit of Advagraf administration de novo after LTx as demonstrated by the European Liver Transplant Registry analysis is confirmed in an independent cohort, Advagraf will leave the area of the &apos;me-too&apos; drugs to become the immunosuppressant of choice.

Název v anglickém jazyce

Once-daily tacrolimus in liver transplantation: a 'me-too drug', or a therapeutic advantage

Popis výsledku anglicky

Purpose of review To provide latest information on differences between standard tacrolimus ( TAC BID) and slow-released formulation of tacrolimus ( Advagraf) in liver transplantation ( LTx), and to discuss the latter&apos;s therapeutic value as a distinct entity. Recent findings Two articles on de-novo studies, several on conversion and one on survival analysis from the European Liver Transplant Registry published recently showed that low-dose Advagraf immediately after transplantation provided same protection to the kidney as standard dose delayed until day 5, and was associated with lower rejection rate; to maintain the same trough level after late conversion to Advagraf, an approximately 1.25-fold higher dose was needed on average; if studied by questionnaire, conversion improved medication adherence; and registry data provided evidence of long-term survival benefit of Advagraf over TAC BID ( 7 and 8% graft and patient survival rates over a 3-year period; P&lt;0.002 and P&lt;0.003, respectively). Summary Pharmacokinetic differences between TAC BID and Advagraf translate into less interpatient and intrapatient variability and improve adherence. If survival benefit of Advagraf administration de novo after LTx as demonstrated by the European Liver Transplant Registry analysis is confirmed in an independent cohort, Advagraf will leave the area of the &apos;me-too&apos; drugs to become the immunosuppressant of choice.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30213 - Transplantation

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current opinion in organ transplantation

ISSN

1087-2418

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

118-122

Kód UT WoS článku

000396215900004

EID výsledku v databázi Scopus

—